AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

United States Triple-Negative Breast Cancer KOL Interview, 2019: Prescribing Habits, Key Marketed Brands, and Late-Phase Pipeline Therapies - ResearchAndMarkets.com

December 23, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Dec 23, 2019--

The “Triple-Negative Breast Cancer KOL Interview - US” report has been added to ResearchAndMarkets.com’s offering.

A US-based key opinion leader provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple-negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed.

Key pipeline assets highlighted include:

For more information about this report visit https://www.researchandmarkets.com/r/d2kmwv

View source version on businesswire.com:https://www.businesswire.com/news/home/20191223005582/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 12/23/2019 05:03 PM/DISC: 12/23/2019 05:03 PM

http://www.businesswire.com/news/home/20191223005582/en